Market closed
Arcturus Therapeutics Holdings/$ARCT
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Arcturus Therapeutics Holdings
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
Ticker
$ARCT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
180
Website
ARCT Metrics
BasicAdvanced
$481M
-
-$2.33
2.64
-
Price and volume
Market cap
$481M
Beta
2.64
52-week high
$45.00
52-week low
$14.30
Average daily volume
414K
Financial strength
Current ratio
4.763
Quick ratio
3.849
Long term debt to equity
9.924
Total debt to equity
9.924
Interest coverage (TTM)
-20,136.75%
Management effectiveness
Return on assets (TTM)
-12.16%
Return on equity (TTM)
-23.12%
Valuation
Price to revenue (TTM)
2.984
Price to book
1.84
Price to tangible book (TTM)
1.84
Price to free cash flow (TTM)
-7.769
Growth
Revenue change (TTM)
-45.85%
Earnings per share change (TTM)
-163.69%
3-year revenue growth (CAGR)
163.14%
3-year earnings per share growth (CAGR)
-32.45%
What the Analysts think about ARCT
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Arcturus Therapeutics Holdings stock.
ARCT Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ARCT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ARCT News
AllArticlesVideos
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
Business Wire·2 weeks ago
Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19
Business Wire·4 weeks ago
Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Arcturus Therapeutics Holdings stock?
Arcturus Therapeutics Holdings (ARCT) has a market cap of $481M as of February 25, 2025.
What is the P/E ratio for Arcturus Therapeutics Holdings stock?
The price to earnings (P/E) ratio for Arcturus Therapeutics Holdings (ARCT) stock is 0 as of February 25, 2025.
Does Arcturus Therapeutics Holdings stock pay dividends?
No, Arcturus Therapeutics Holdings (ARCT) stock does not pay dividends to its shareholders as of February 25, 2025.
When is the next Arcturus Therapeutics Holdings dividend payment date?
Arcturus Therapeutics Holdings (ARCT) stock does not pay dividends to its shareholders.
What is the beta indicator for Arcturus Therapeutics Holdings?
Arcturus Therapeutics Holdings (ARCT) has a beta rating of 2.64. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.